Selank peptide research: proposed mechanisms and evidence quality
Evidence summary: Selank is the tuftsin-derived heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. Research has examined GABAergic gene expression, enkephalin-degrading enzymes, neurotrophins and anxiety-related models. No single primary receptor has been established, and the human literature consists mainly of small Russian clinical reports rather than large independently replicated trials.
Key findings
- Selank extends the immune peptide tuftsin with a Pro-Gly-Pro tail.
- Published mechanisms span several systems; no single receptor explains all reported findings.
- Clinical reports are limited in size, geography and independent replication.
From tuftsin to Selank
Tuftsin is the natural tetrapeptide Thr-Lys-Pro-Arg, released from immunoglobulin G and associated with immune signalling. Selank adds Pro-Gly-Pro to that sequence, producing a seven-residue molecule designed for greater stability.
Its origin distinguishes Selank from Semax, which derives from an ACTH fragment. The shared Pro-Gly-Pro tail does not make their parent molecules or evidence bases equivalent.
GABAergic gene-expression findings
In rats, Selank exposure altered expression of genes involved in GABAergic neurotransmission in frontal-cortex tissue. This supports investigating GABA-related pathways, but it does not identify Selank as a direct GABA-receptor agonist.
Gene-expression changes are sensitive to tissue, timepoint and model. They should be interpreted as mechanistic signals rather than direct evidence of a human anxiolytic outcome.
Enkephalin metabolism and opioid-system clues
In vitro work reported inhibition of enkephalin-degrading enzymes in human plasma. Separate mouse studies found that naloxone altered some behavioural effects, suggesting an indirect relationship with endogenous opioid signalling.
These findings do not mean Selank is an opioid agonist. Enzyme inhibition in plasma and antagonist-sensitive behaviour are distinct observations that require follow-up to establish a molecular target.
What the clinical reports contribute
Small Russian reports describe Selank in generalized anxiety disorder, neurasthenia and other anxiety-related settings. They establish that clinical observation has occurred, but do not provide the large, multicentre, blinded and independently replicated evidence expected for broad efficacy conclusions.
Differences in diagnostic criteria, reporting standards and access to full study methods also make direct comparison with modern trials difficult.
What remains unresolved
A primary receptor target has not been established. The relative contribution of GABAergic expression, enkephalin metabolism, BDNF-related findings and immune signalling remains uncertain, and much of the work comes from a limited research network.
Future studies need predefined endpoints, appropriate controls, sequence and purity verification, and independent replication across laboratories.
Continue to the full evidence guide
Read the complete Selank research guide
Frequently asked questions
What is Selank peptide derived from?
Selank is derived from tuftsin, with a Pro-Gly-Pro tail added to the natural four-amino-acid sequence.
Does Selank bind directly to GABA receptors?
A primary direct GABA-receptor interaction has not been established; published work reports changes in GABAergic gene expression.
Is Selank an opioid?
No. Some studies suggest an indirect relationship with endogenous opioid signalling, but Selank is not established as an opioid-receptor agonist.
What human evidence exists for Selank?
Small Russian clinical reports exist, but large independently replicated blinded trials are lacking.
Is Selank for human use?
No. PeptidesDirect supplies Selank strictly for laboratory research, not human or veterinary use.
Primary references
- Zozulia AA, et al. Efficacy and possible mechanisms of action of selank in generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed 18454096
- Volkova A, et al. Selank administration affects the expression of genes involved in GABAergic neurotransmission. Front Pharmacol. 2016. PubMed 26924987
- Zolotarev IuA, et al. Selank inhibition of enkephalin-degrading enzymes of human plasma. Bioorg Khim. 2004. PubMed 15344652
Related research materials
Research Use Only. Not for human or veterinary use. This page is not dosing or medical guidance.
